TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest

Trial Profile

TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs 2-iminobiotin (Primary)
  • Indications Asphyxia
  • Focus Adverse reactions
  • Acronyms TIBOHCA
  • Most Recent Events

    • 26 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 26 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 21 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top